286
-1.38%
Close of 9 Nov 2026, in IDR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Diagnos Laboratorium Utama PT Tbk
Its shares trade on IDX under the ticker DGNS.JK. It has been listed since 15 January 2021. In the fiscal year to 31 December 2025, it reported revenue of IDR 166.62bn and net income of IDR 2.94bn. At that date it held total assets of IDR 318.67bn and shareholders' equity of IDR 203.99bn.
PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. The company employs 90 full-time employees The company went IPO on 2021-01-15. The Company’s scope of activities also includes private clinical activities. Its products and services include clinical pathology laboratory tests, anatomical pathology laboratory tests, genomics laboratory tests, homecare health tests, corporate health tests and Covid-19 tests. Its clinical pathology laboratory provides services ranging from molecular examinations to support more treatment. Its clinical pathology laboratory provides services for examination of hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology and microbiology. The services provided at the genetic laboratory are non-invasive prenatal testing (NIPT), preimplantation genetic testing for aneuploidy (PGT-A) services, and preimplantation genetic testing for monogenic diseases (PGT-M) services. Its homecare health services provide health checks that are done at home.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 15 Jan 2021
- Employees
- 90
- Website
- diagnos.co.id ↗
Leadership
Pay as last reported
- Mr. Ivan SiniPresident Commissioner
- Mr. Mesha SiniPresident Director
- Mr. Fergus RichardDirector - Finance, Accounting & IT
- Mr. Dennis JacobusManaging Director
- Ms. Dilly DwiasriDirector - Operations & Marketing
- Ms. Renobulan Sini SuheimiDirector
- Mr. Fanfan RiksaniCorporate Secretary
- Mr. Nurhadi YudiyanthoCommissioner
- Mr. Martinus ZegaIndependent Commissioner
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PT Diagnos Laboratorium Utama Tbk employs 90 full-time staff members.
- The company provides clinical pathology laboratory tests for molecular examinations.
- Genomics laboratory tests include non-invasive prenatal testing services for patients.
Weaknesses
- The company has only 90 employees for its operations.
- PT Diagnos Laboratorium Utama Tbk went public on 15 January 2021.
- Homecare health tests are limited to specific geographic areas.
Opportunities
- Covid-19 tests offer new revenue streams for the company.
- Corporate health tests can expand the client base significantly.
- Anatomical pathology laboratory tests support more comprehensive treatment options.
Threats
- Private clinical activities face competition from established healthcare providers.
- Molecular examinations require continuous investment in advanced laboratory technology.
- Genomics laboratory tests may face regulatory changes in Indonesia.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.